Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with healthy free cash flow and strong balance sheets, while Coca-Cola remains safe despite higher payout ratios. PepsiCo, however, faces risk as its dividend consumes nearly all free cash flow, requiring strong cash flow conversion to maintain its streak. All four companies raised dividends modestly this year, maintaining long-term payout growth streaks, but PepsiCo's financial cushion is thinner compared to the others.
Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo show varied investor interest on Pluang, with Johnson & Johnson seeing 96% buy orders and a dividend yield of 2.09%. PepsiCo offers the highest dividend yield at 4.61% but has a shorter typical hold time of 107 days. These figures are current as of Oct 09, 2026 19:11 WIB.
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of ...
Five major U.S. companies—Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Realty Income—are highlighted for their long histories of dividend increases and strong cash flow coverage. These firms offer diverse dividend yields, with some pr...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
Johnson & Johnson has achieved its 64th consecutive year of dividend increases, raising its quarterly dividend by 3.1% to $1.34 per share in 2026. Despite strong overall sales growth driven by new drugs like Tremfya and Darzalex, the company faces si...
